The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2025
The impact of hormonal contraceptives containing estradiol, estradiol valerate, and estetrol on liver proteins, lipids, glucose, blood pressure, and bone. A literature review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cagnacci Angelo, Xholli Anjeza, Gabbi Laura, Russo Alessia, Pastorino Rachele, Londero Ambrogio Pietro
Аннотация
OBJECTIVE: We investigated the metabolic profile induced by contraceptives containing body-identical oestrogens.
METHODS: A literature search was made for articles on contraceptives with oestradiol/nomegestrol acetate (E2/NOMAc), oestradiol valerate/dienogest (E2V/DNG), estetrol/drospirenone (E4/DRSP) and metabolic parameters.
RESULTS: The three formulations induced a similar, slight but significant increase of liver proteins. Levels of angiotensinogen were measured only during E4/DRSP, and were significantly increased (p < 0.05). Scanty data indicate a neutral effect of the three formulations on blood pressure. Lipids and lipoproteins were not modified by E2/NOMAc and E2V/DNG, while triglycerides slightly but significantly increased (p < 0.05) during E4/DRSP. Fasting glucose was unaffected by any association while fasting insulin increased during E2/NOMAc and E2V/DNG. Data were not reported for E4/DRSP. Insulin resistance was increased by E4/DRSP and not by E2V/DNG. Bone turnover was tested only in users of E2V/DNG. Markers of bone formation did not change while markers of bone absorption decreased. Bone mineral density (BMD) did not change after 6 months of E2V/DNG and after 2 years of E2/NOMAc. No data on BMD is available for users of E4/DRSP.
CONCLUSIONS: The three contraceptive formulations exert a similar, almost neutral effect on metabolism and blood pressure. Only a slight increase of triglycerides and a decrease of insulin sensitivity emerged with the use of E4/DRSP. The few data on bone, suggest a neutral effect of E2V/DNG and E2/NOMAc. There is no data evaluating the effect of the contraceptive association of E4/DRSP on bone.
METHODS: A literature search was made for articles on contraceptives with oestradiol/nomegestrol acetate (E2/NOMAc), oestradiol valerate/dienogest (E2V/DNG), estetrol/drospirenone (E4/DRSP) and metabolic parameters.
RESULTS: The three formulations induced a similar, slight but significant increase of liver proteins. Levels of angiotensinogen were measured only during E4/DRSP, and were significantly increased (p < 0.05). Scanty data indicate a neutral effect of the three formulations on blood pressure. Lipids and lipoproteins were not modified by E2/NOMAc and E2V/DNG, while triglycerides slightly but significantly increased (p < 0.05) during E4/DRSP. Fasting glucose was unaffected by any association while fasting insulin increased during E2/NOMAc and E2V/DNG. Data were not reported for E4/DRSP. Insulin resistance was increased by E4/DRSP and not by E2V/DNG. Bone turnover was tested only in users of E2V/DNG. Markers of bone formation did not change while markers of bone absorption decreased. Bone mineral density (BMD) did not change after 6 months of E2V/DNG and after 2 years of E2/NOMAc. No data on BMD is available for users of E4/DRSP.
CONCLUSIONS: The three contraceptive formulations exert a similar, almost neutral effect on metabolism and blood pressure. Only a slight increase of triglycerides and a decrease of insulin sensitivity emerged with the use of E4/DRSP. The few data on bone, suggest a neutral effect of E2V/DNG and E2/NOMAc. There is no data evaluating the effect of the contraceptive association of E4/DRSP on bone.